World Wires · story 24092 · unverified · 1 source(s)

NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt

NeOnc’s (NASDAQ: NTHI) investigational brain-cancer programs, NEO100 and NEO212, have upcoming FDA catalysts

Open in the desk

Coverage

• NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt GlobeNewswire: public companies · tier D · clear net · 2026-10-06 13:02 UTC

What this site indexes